Citi resumed coverage of Pfizer (PFE) with a Neutral rating and $26 price target The firm has a balanced view on the shares. The company’s operational efficiencies and policy certainty are balanced by “substantial” medium-term headwinds from Medicare Part D pressures, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Prasad email a headwind for vaccine manufacturers, says BofA
- Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- US government confirms agreement in principle with UK on pharmaceutical pricing